Skipping chemotherapy in early breast cancer with CDK4/6 inhibitor
Part of Cancer, Skin clinical trials.
This trial tests whether it is safe to skip chemotherapy after surgery for certain patients with early-stage, hormone-receptor positive, HER2-negative breast cancer that has not spread to lymph nodes. Instead, they would receive hormone therapy plus a targeted CDK4/6 inhibitor (a pill that blocks cancer cell growth).
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old.
- You have early-stage breast cancer that is HR-positive and HER2-negative, with no cancer in your lymph nodes (node-negative).
- Your tumor shows certain high-risk features (like a high grade or rapid cell growth measured by Ki67 or a high-risk genetic test).
- You have not had chemotherapy, radiation, or hormone therapy before surgery for this breast cancer.
- You are otherwise healthy enough for treatment, with normal blood counts and organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if women with a common type of breast cancer (HR+/HER2-) can safely skip chemotherapy after surgery by taking targeted medication (ribociclib) plus hormone therapy. A special blood test called ctDNA helps doctors decide if chemo isn't needed.
This trial tests whether adding a CDK4/6 inhibitor (a type of targeted pill) to standard hormone therapy after surgery can lower the risk of breast cancer coming back in women with high-risk, hormone-receptor-positive, HER2-positive early breast cancer.
This trial tests whether skipping chemotherapy is safe for women with a specific type of early-stage breast cancer (ER-positive, HER2-negative) that has spread to 1–3 lymph nodes. Instead of chemo, you would receive a targeted pill called abemaciclib after standard hormone therapy.
This trial tests whether a CDK4/6 inhibitor given after surgery can help prevent breast cancer from coming back. It is for people with HR-positive, HER2-negative breast cancer that has not spread to other parts of the body.
This trial tests a stronger treatment (a CDK4/6 inhibitor) combined with less chemotherapy for early-stage breast cancer that is positive for hormone receptors and HER2. It aims to see if this approach works well while reducing side effects from chemo.
This trial tests whether women with certain aggressive breast cancers (HER2-positive without hormone receptors, or triple-negative) can safely skip breast surgery if chemotherapy makes their tumor completely disappear. The goal is to avoid surgery and its side effects when it may no longer be needed.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.